Back
Neurocrine Biosciences 10K Form
Buy
57
NBIX
Neurocrine Biosciences
Last Price:
126.70
Seasonality Move:
17.1%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-01 | 10Q | NBIX/Neurocrine Biosciences Quarterly |
| 2023-10-31 | 10Q | NBIX/Neurocrine Biosciences Quarterly |
| 2023-08-01 | 10Q | NBIX/Neurocrine Biosciences Quarterly |
| 2023-05-03 | 10Q | NBIX/Neurocrine Biosciences Quarterly |
| 2022-11-01 | 10Q | NBIX/Neurocrine Biosciences Quarterly |
| 2022-08-04 | 10Q | NBIX/Neurocrine Biosciences Quarterly |
Receive NBIX News And Ratings
See the #1 stock for the next 7 days that we like better than NBIX
NBIX Financial Statistics
Sales & Book Value
| Annual Sales: | $1.89B |
|---|---|
| Cash Flow: | $149.9M |
| Price / Cash Flow: | 29.55 |
| Annual Sales: | $26.87 |
| Price / Book: | 4.68 |
Profitability
| EPS (TTM): | 3.73000 |
|---|---|
| Net Income (TTM): | $385.9M |
| Gross Margin: | $1.85B |
| Return on Equity: | 16.29% |
| Return on Assets: | 11.76% |
Neurocrine Biosciences Earnings Forecast
Key Neurocrine Biosciences Financial Ratios
- The Gross Profit Margin over the past 28 years for NBIX is 97.90%.
- The Selling, General & Administrative Expenses for NBIX have been equal to 47.04% of Gross Profit Margin.
- The Research & Development expenses have been 29.94% of Revenue.
- The Interest Expense is 1.84% of Operating Income.
- The Net Earning history of NBIX is 13.23% of Total Revenues.
- Per Share Earnings over the last 28 years have been positive in 13 years.
Neurocrine Biosciences Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NBIX |
| CUSIP: | 64125C |
| Website: | neurocrine.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 4.37 |
| Quick Ratio: | 3.98 |
Price-to-Earnings
| Trailing P/E Ratio: | 50.87 |
|---|---|
| Forward P/E Ratio: | 16.37 |
NBIX Technical Analysis vs Fundamental Analysis
Buy
57
Neurocrine Biosciences (NBIX)
is a Buy
Is Neurocrine Biosciences a Buy or a Sell?
-
Neurocrine Biosciences stock is rated a Buy
The current Neurocrine Biosciences [NBIX] share price is $125.65. The Score for NBIX is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.